<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03429738</url>
  </required_header>
  <id_info>
    <org_study_id>PMRI study number 2014-3489</org_study_id>
    <nct_id>NCT03429738</nct_id>
  </id_info>
  <brief_title>Single-Dose Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride Tablets</brief_title>
  <official_title>A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride 200 mg/30 mg Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharma Medica Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the comparative bioavailability between two oral formulations containing&#xD;
      ibuprofen 200 mg and pseudoephedrine 30 mg after a single dose in healthy subjects under&#xD;
      fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ibuprofen is one of the most often used non steroidal antiinflammatory drug (NSAR) in the&#xD;
      management of mild to moderate pain and inflammation. Combined with the sympathomimetic&#xD;
      pseudoephedrine as decongestant it is widely used in colds or fever. The purpose of this&#xD;
      phase-I-study was to evaluate the comparative bioavailability between a combination of 200 mg&#xD;
      ibuprofen and 30 mg pseudoephedrine film-coated tablets to the reference formulation&#xD;
      RhinAdvil Rhume® 200 mg/30 mg (Wyeth Santé Familiale, France).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2014</start_date>
  <completion_date type="Actual">May 5, 2014</completion_date>
  <primary_completion_date type="Actual">May 5, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>open-label, single-dose, randomized, two-period, two-treatment, twosequence, crossover, comparative bioavailability study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-t) (area under the analyte concentration versus time curve) of ibuprofen and pseudoephedrine, respectively</measure>
    <time_frame>7 days (± 3 hours)</time_frame>
    <description>The 90% confidence intervals of the relative mean plasma (1S,2S)- pseudoephedrine and (S) ibuprofen AUC should be between 80.00 and 125.00%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum serum concentration of ibuprofen and pseudoephedrine, respectively</measure>
    <time_frame>7 days (± 3 hours)</time_frame>
    <description>The 90% confidence intervals of the relative mean plasma (1S,2S)- pseudoephedrine and (S) ibuprofen Cmax should be between 80.00 and 125.00%</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Pain, Head</condition>
  <condition>Pain, Acute</condition>
  <condition>Pain, Back</condition>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets</intervention_name>
    <description>Experimental drug</description>
    <arm_group_label>Experimental Drug</arm_group_label>
    <other_name>Ibuprofen/Pseudoephedrine/test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Active Comparator</arm_group_label>
    <other_name>RhinAdvil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, non-smoking, male and female subjects, 18 years of age or older.&#xD;
&#xD;
          2. BMI ≥ 18.5 and 30.0 kg/m2&#xD;
&#xD;
          3. No clinically significant findings in vital signs measurements.&#xD;
&#xD;
          4. No clinically significant abnormal laboratory values.&#xD;
&#xD;
          5. No clinically significant findings in a 12-lead electrocardiogram (ECG).&#xD;
&#xD;
          6. No significant diseases.&#xD;
&#xD;
          7. Willing to use an acceptable, effective method of contraception.&#xD;
&#xD;
          8. Be informed of the nature of the study and give written consent prior to any study&#xD;
             procedure.&#xD;
&#xD;
          9. Have no clinically significant findings from a physical examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history or presence of any clinically significant medical condition.&#xD;
&#xD;
          2. Known or suspected carcinoma.&#xD;
&#xD;
          3. History or presence of ulcerative colitis, diverticulosis, Crohn's disease, or&#xD;
             gastrointestinal ulcer, perforation, or haemorrhage.&#xD;
&#xD;
          4. Known history or presence of auto-immune disorders, gastrointestinal toxicity, or a&#xD;
             risk of gastrointestinal bleeding or gastrointestinal tract irritation.&#xD;
&#xD;
          5. Known history or presence of cardiovascular disease, heart failure, tachycardia,&#xD;
             hypertension, angina pectoris, hyperthyroidism, psychosis, seizures, risk of urinary&#xD;
             retention, diabetes, phaeochromocytoma, closed angle glaucoma, chronic rhinitis, or&#xD;
             prostatic enlargement.&#xD;
&#xD;
          6. Known history or presence of angioedema.&#xD;
&#xD;
          7. Known history or presence of galactose or fructose intolerance, sucraseisomaltase&#xD;
             insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose&#xD;
             malabsorption syndrome.&#xD;
&#xD;
          8. Known history of severe skin reactions (e.g. exfoliative dermatitis, SJS, and TEN).&#xD;
&#xD;
          9. Known history or presence of bronchial asthma or allergic disease resulting in&#xD;
             bronchospasm.&#xD;
&#xD;
         10. Presence of hepatic or renal dysfunction.&#xD;
&#xD;
         11. Presence of clinically significant gastrointestinal disease or history of&#xD;
             malabsorption within the last year.&#xD;
&#xD;
         12. Presence of a medical condition requiring regular medication (prescription and/or&#xD;
             over-the-counter) with systemic absorption.&#xD;
&#xD;
         13. History of drug or alcohol addiction requiring treatment.&#xD;
&#xD;
         14. History of gastrointestinal bleeding or perforation when previously taking NSAIDs.&#xD;
&#xD;
         15. Positive test result for HIV, Hepatitis B surface antigen or Hepatitis C antibody.&#xD;
&#xD;
         16. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines,&#xD;
             cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and&#xD;
             benzodiazepines) or urine cotinine.&#xD;
&#xD;
         17. Difficulty fasting or consuming standard meals.&#xD;
&#xD;
         18. Does not tolerate venipuncture.&#xD;
&#xD;
         19. Use of tobacco or nicotine-containing products within 6 months prior to drug&#xD;
             administration.&#xD;
&#xD;
         20. On a special diet within 30 days prior to drug administration (e.g., liquid, protein,&#xD;
             raw food diet).&#xD;
&#xD;
         21. Participated in another clinical trial or received an investigational product within&#xD;
             30 days prior to drug administration.&#xD;
&#xD;
         22. Donation or loss of whole blood (including clinical trials):&#xD;
&#xD;
               -  50 mL and ≤ 499 mL within 30 days prior to drug administration&#xD;
&#xD;
               -  500 mL within 56 days prior to drug administration.&#xD;
&#xD;
         23. Females who:&#xD;
&#xD;
             Have discontinued or changed the use of implanted, intrauterine, intravaginal, or&#xD;
             injected hormonal contraceptives within 6 months prior to dosing; Have discontinued or&#xD;
             changed the use of oral or patch hormonal contraceptives within 1 month prior to drug&#xD;
             administration; Are pregnant (serum hCG consistent with pregnancy); or Are lactating.&#xD;
&#xD;
         24. Have had a tattoo or body piercing within 30 days prior to drug administration.&#xD;
&#xD;
         25. Known history or presence of hypersensitivity or idiosyncratic reaction to ibuprofen,&#xD;
             pseudoephedrine, NSAIDs, or any other drug substances with similar activity or any of&#xD;
             the excipients in the drug products&#xD;
&#xD;
         26. Use of drugs in the phenethylamine and amphetamine chemical classes within 14 days&#xD;
             prior to drug administration.&#xD;
&#xD;
         27. Use of NSAIDs (including cyclo-oxygenase-2 selective inhibitors) aspirin,&#xD;
             corticosteroids, anticoagulants, selective serotonin-reuptake inhibitors,&#xD;
             antihypertensives, diuretics, cardiac glycosides, lithium, methotrexate, cyclosporin,&#xD;
             mifepristone, tacrolimus, zidovudine, linezolid, dopaminergic alkaloids, quinolone&#xD;
             antibiotics, terpene derivatives, clobutinol, atropine, local anaesthetics, MAO&#xD;
             inhibitors, vasoconstrictors, alpha sympathomimetic drugs, or anti-platelet agents&#xD;
             within 30 days prior to drug administration.&#xD;
&#xD;
         28. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days&#xD;
             prior to drug administration. (e.g. barbiturates, carbamazepine, phenytoin,&#xD;
             glucocorticoids, omeprazole, antidepressants (SSRI), cimetidine, diltiazem,&#xD;
             macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Latifa Yamlahi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharma Medica Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Medica Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>MIS 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ibuprofen</keyword>
  <keyword>phase-I-study</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>combination therapy</keyword>
  <keyword>bioavailability</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>pseudoephedrine hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no IPD to be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

